CLINICAL AND ONCOLOGICAL OUTCOME OF SALVAGE CYSTECTOMY AFTER RADIOTHERAPY FAILURE IN BLADDER CANCER

Main Article Content

Shaukat Fiaz
Azfar Ali
Sidiqque Adnan
Zubair Ahmad Cheema
Muhammad Abubakar
Khuram Mir

Abstract

Objectives: To analyze the clinical and oncological outcomes of Salvage Cystectomy after radiotherapy failure in bladder cancer.


Methodology: A retrospective study was conducted over a 12-year period (January 2005 to December 2017) at the Uro-oncology department of the Shaukat Khanum Memorial Cancer Hospital and Research Center, involving 21 patients who underwent salvage cystectomy. The patients were monitored through cystourethroscopy and imaging (CT/MRI) after receiving chemo-radiotherapy for bladder cancer. Those with histologically confirmed recurrence of malignancy were eligible for salvage cystectomy, excluding metastatic and non-resectable cases. Survival was calculated using the Kaplan-Meier method, and complications were divided into early and late categories.


Results: Of the 21 patients, 86% were male. The median age was 60 years (range, 45-73 years). The median fol­low-up duration from time of cystectomy was 43 months (range, 5-103 months). The three and five years disease free survival rates were 60% and 47%, respectively, while the calculated three and five years overall survival rates were 58% and 43%, respectively. RC with ileal conduit was performed in all patients. Tumor under staging was noted in 57 % of cases. Distant metastasis was reported in 12 patients (two patients had both local and distant recurrence). Of the 16 cases with complications, early complications (within a month) and delayed complications (after a month) were 9(43%) and 7(33%) respectively.


Conclusion: Salvage cystectomy remains a viable option with acceptable morbidity in bladder-sparing treatment failure for muscle-invasive bladder cancer.

Article Details

How to Cite
1.
Fiaz S, Ali A, Adnan S, Cheema ZA, Muhammad Abubakar, Mir K. CLINICAL AND ONCOLOGICAL OUTCOME OF SALVAGE CYSTECTOMY AFTER RADIOTHERAPY FAILURE IN BLADDER CANCER. J Postgrad Med Inst [Internet]. 2023 Mar. 1 [cited 2024 Mar. 28];37(1):31-5. Available from: https://jpmi.org.pk/index.php/jpmi/article/view/3039
Section
Original Article
Author Biographies

Azfar Ali, Department of Uro-oncology, Shaukat Khanum Memorial Cancer Hospital & Research Center, Lahore

Assistant Professor, Urology 

Lahore General Hospital.

Sidiqque Adnan, Department of Uro-oncology, Shaukat Khanum Memorial Cancer Hospital & Research Center, Lahore

Consultant Urologist,

Kabir Medical College, Peshawar

Zubair Ahmad Cheema, Department of Uro-oncology, Shaukat Khanum Memorial Cancer Hospital & Research Center, Lahore

Consultant Urologist,

Shaukat Khanum Memorial Cancer Hospital and Research Center, Lahore.

Muhammad Abubakar, Department of Uro-oncology, Shaukat Khanum Memorial Cancer Hospital & Research Center, Lahore

Cancer Epidemiology and biostatistician, 

Shaukat Khanum Memorial Cancer Hospital and Research Center, Lahore.

Khuram Mir, Department of Uro-oncology, Shaukat Khanum Memorial Cancer Hospital & Research Center, Lahore

Consultant Urologist,

Shaukat Khanum Memorial Cancer Hospital and Research Center, Lahore.

References

Ferlay J, Colombet M, Soerjomataram I, Dyba T, Randi G, Bettio M, et al. Cancer incidence and mortality patterns in Europe: Estimates for 40 countries and 25 major cancers in 2018. Eur J Cancer. 2018;103:356-87. DOI:10.1016/j. ejca.2018.07.005.

Gakis G, Efstathiou J, Lerner SP, Cookson MS, Keegan KA, Guru KA, et a. ICUD-EAU International Consultation on Bladder Cancer 2012: Radical cystectomy and bladder preservation for muscle-invasive urothelial carcinoma of the bladder. Eur Urol. 2013;63(1):45-57. DOI:10.1016/j.eururo.2012.08.009.

Novara G, De Marco V, Aragona M, Boscolo-Berto R, Cavalleri S, Artibani W, et al. Complications and mortality after radical cystectomy for bladder transitional cell cancer. J Urol. 2009;182(3):914-21. DOI:10.1016/j. juro.2009.05.032.

Donat SM, Shabsigh A, Savage C, Cronin AM, Bochner BH, Dalbagni G, et al. Potential impact of postoperative early complications on the timing of adjuvant chemotherapy in patients undergoing radical cystectomy: a high-volume tertiary cancer center experience. Eur Urol. 2009;55(1):177-85. DOI:10.1016/j. eururo.2008.07.018.

Gerharz EW, Mansson A, Hunt S, Skinner EC, Mansson W. Quality of life after cystectomy and urinary diversion: an evidence based analysis. J Urol. 2005;174(5):1729- 36. DOI:10.1097/01. ju.0000176463.40530.05.

Henningsohn L, Steven K, Kallestrup EB, Steineck G. Distressful symptoms and well-being after radical cystectomy and orthotopic bladder substitution compared with a matched control population. J Urol. 2002;168(1):168- 74; discussion 174-5. DOI:10.1016/ s0022-5347(05)64854-9.

Shipley WU, Kaufman DS, Zehr E, Heney NM, Lane SC, Thakral HK, et al. Selective bladder preservation by combined modality protocol treatment: long-term outcomes of 190 patients with invasive bladder cancer. Urology. 2002;60(1):62-7; discussion 67-8. DOI:10.1016/s0090-4295(02)01650- 3.

Schuster TG, Marcovich R, Sheffield J, Montie JE, Lee CT. Radical cystectomy for bladder cancer after definitive prostate cancer treatment. Urology. 2003 Feb;61(2):342-7; discussion 347. DOI:10.1016/s0090-4295(02)02272- 0.

Efstathiou JA, Bae K, Shipley WU, Kaufman DS, Hagan MP, Heney NM, et al. Late pelvic toxicity after bladder-sparing therapy in patients with invasive bladder cancer: RTOG 89-03, 95-06, 97-06, 99-06. J Clin Oncol. 2009;27(25):4055-61. DOI:10.1200/ JCO.2008.19.5776.

Zietman AL, Sacco D, Skowronski U, Gomery P, Kaufman DS, Clark JA, et al. Organ conservation in invasive bladder cancer by transurethral resection, chemotherapy and radiation: results of a urodynamic and quality of life study on long-term survivors. J Urol. 2003;170(5):1772-6. DOI:10.1097/01. ju.0000093721.23249.c3.

Dixon AK, Deane AM, Doyle PT. Computed tomography and magnetic resonance imaging before salvage cystectomy. Br J Urol. 1990;66(1):42-6. DOI:10.1111/j.1464-410x.1990. tb14863.x.

Droller MJ, Walsh PC. Therapeutic efficacy of salvage cystectomy. Do results reflect natural history of bladder cancer? Urology. 1983;22(2):118-22. DOI:10.1016/0090-4295(83)90489-2.

Nieuwenhuijzen JA, Horenblas S, Meinhardt W, van Tinteren H, Moonen LM. Salvage cystectomy after failure of interstitial radiotherapy and external beam radiotherapy for bladder cancer. BJU Int. 2004;94(6):793-7. DOI:10.1111/ j.1464-410X.2004.05034.x.

Eswara JR, Efstathiou JA, Heney NM, Paly J, Kaufman DS, McDougal WS, et al. Complications and long-term results of salvage cystectomy after failed bladder sparing therapy for muscle invasive bladder cancer. J Urol. 2012;187(2):463-8. DOI:10.1016/j. juro.2011.09.159.

Efstathiou JA, Spiegel DY, Shipley WU, et al. Long-term outcomes of selective bladder preservation by combined-modality therapy for invasive bladder cancer: the MGH experience. Eur Urol. 2012;61:705e711. DOI:10.1016/j. eururo.2011.11.010

Bochner BH, Figueroa AJ, Skinner EC, Lieskovsky G, Petrovich Z, Boyd SD, Skinner DG. Salvage radical cystoprostatectomy and orthotopic urinary diversion following radiation failure. J Urol. 1998;160(1):29-33. DOI:10.1016/ s0022-5347(01)63018-0

Wammack R, Wricke C, Hohenfellner R. Long-term results of ileocecal continent urinary diversion in patients treated with and without previous pelvic irradiation. J Urol. 2002;167(5):2058-62. DOI:10.1016/S0022-5347(05)65083- 5.

Eisenberg MS, Dorin RP, Bartsch G, Cai J, Miranda G, Skinner EC. Early complications of cystectomy after high dose pelvic radiation. J Urol. 2010;184(6):2264-9. DOI:10.1016/j. juro.2010.08.007.